Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis

In the past years, several theories have been advanced to explain the pathogenesis of Major Depressive Disorder (MDD), a neuropsychiatric disease that causes disability in general population. Several theories have been proposed to define the MDD pathophysiology such as the classic “monoamine-theory” or the “glutamate hypothesis.” All these theories have been recently integrated by evidence highlighting inflammation as a pivotal player in developing depressive symptoms. Proinflammatory cytokines have been indeed claimed to contribute to stress-induced mood disturbances and to major depression, indicating a widespread role of classical mediators of inflammation in emotional control. Moreover, during systemic inflammatory diseases, peripherally released cytokines circulate in the blood, reach the brain and cause anxiety, anhedonia, social withdrawal, fatigue, and sleep disturbances. Accordingly, chronic inflammatory disorders, such as the inflammatory autoimmune disease multiple sclerosis (MS), have been associated to higher risk of MDD, in comparison with overall population. Importantly, in both MS patients and in its experimental mouse model, Experimental Autoimmune Encephalomyelitis (EAE), the notion that depressive symptoms are reactive epiphenomenon to the MS pathology has been recently challenged by the evidence of their early manifestation, even before the onset of the disease. Furthermore, in association to such mood disturbance, inflammatory-dependent synaptic dysfunctions in several areas of MS/EAE brain have been observed independently of brain lesions and demyelination. This evidence suggests that a fine interplay between the immune and nervous systems can have a huge impact on several neurological functions, including depressive symptoms, in different pathological conditions. The aim of the present review is to shed light on common traits between MDD and MS, by looking at inflammatory-dependent synaptic alterations associated with depression in both diseases.

[1]  D. Gomez-Nicola,et al.  Involvement of Wnt7a in the role of M2c microglia in neural stem cell oligodendrogenesis , 2020, Journal of Neuroinflammation.

[2]  S. Di Nuovo,et al.  The cytokine network in the pathogenesis of major depressive disorder. Close to translation? , 2020, Autoimmunity reviews.

[3]  D. Centonze,et al.  ‘Prototypical’ proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting , 2020, Expert opinion on therapeutic targets.

[4]  T. Bisogno,et al.  Cannabinoids and the expanded endocannabinoid system in neurological disorders , 2019, Nature Reviews Neurology.

[5]  J. Hillert,et al.  Disability worsening among persons with multiple sclerosis and depression , 2019, Neurology.

[6]  A. Araque,et al.  In vivo knockdown of astroglial glutamate transporters GLT-1 and GLAST increases excitatory neurotransmission in mouse infralimbic cortex: Relevance for depressive-like phenotypes , 2019, European Neuropsychopharmacology.

[7]  B. Barak,et al.  Microglia roles in synaptic plasticity and myelination in homeostatic conditions and neurodevelopmental disorders , 2019, Glia.

[8]  H. Ge,et al.  Selecting an Appropriate Animal Model of Depression , 2019, International journal of molecular sciences.

[9]  D. Centonze,et al.  Immunomodulatory Effects of Exercise in Experimental Multiple Sclerosis , 2019, Front. Immunol..

[10]  M. Hotopf,et al.  Emotional outcomes in clinically isolated syndrome and early phase multiple sclerosis: a systematic review and meta-analysis. , 2019, Journal of psychosomatic research.

[11]  V. Yong,et al.  When encephalitogenic T cells collaborate with microglia in multiple sclerosis , 2019, Nature Reviews Neurology.

[12]  F. Giuliani,et al.  The Role of Inflammation in Depression and Fatigue , 2019, Front. Immunol..

[13]  C. Peixoto,et al.  Novel insights into the mechanisms underlying depression-associated experimental autoimmune encephalomyelitis , 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[14]  M. Ramanathan,et al.  Epidemiology and treatment of multiple sclerosis in elderly populations , 2019, Nature Reviews Neurology.

[15]  H. Okamura,et al.  Interleukin-18-deficient mice develop hippocampal abnormalities related to possible depressive-like behaviors , 2019, Neuroscience.

[16]  A. Bortolozzi,et al.  Regionally selective knockdown of astroglial glutamate transporters in infralimbic cortex induces a depressive phenotype in mice , 2019, Glia.

[17]  R. Hester,et al.  Neuroprotective Benefits of Antidepressants in Multiple Sclerosis: Are We Missing the Mark? , 2019, The Journal of neuropsychiatry and clinical neurosciences.

[18]  C. Pariante,et al.  Microglial-driven changes in synaptic plasticity: A possible role in major depressive disorder , 2019, Psychoneuroendocrinology.

[19]  R. Duman,et al.  Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions , 2019, Front. Cell. Neurosci..

[20]  J. Kool,et al.  Influence of different rehabilitative aerobic exercise programs on (anti-) inflammatory immune signalling, cognitive and functional capacity in persons with MS – study protocol of a randomized controlled trial , 2019, BMC Neurology.

[21]  A. Meissner,et al.  T-Cell Accumulation in the Hypertensive Brain: A Role for Sphingosine-1-Phosphate-Mediated Chemotaxis , 2019, International journal of molecular sciences.

[22]  S. Duan,et al.  Cannabinoid CB1 receptors in the amygdalar cholecystokinin glutamatergic afferents to nucleus accumbens modulate depressive-like behavior , 2019, Nature Medicine.

[23]  Bingqian Zhu,et al.  Repetitive transcranial magnetic stimulation increases serum brain-derived neurotrophic factor and decreases interleukin-1β and tumor necrosis factor-α in elderly patients with refractory depression , 2019, The Journal of international medical research.

[24]  S. Strother,et al.  Cortical thickness in major depressive disorder: A systematic review and meta-analysis , 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[25]  P. Croarkin,et al.  Transcranial Magnetic Stimulation for Adolescent Depression. , 2019, Child and adolescent psychiatric clinics of North America.

[26]  Lin Yu,et al.  Effect of selective serotonin reuptake inhibitor on prefrontal-striatal connectivity is dependent on the level of TNF-α in patients with major depressive disorder , 2018, Psychological Medicine.

[27]  D. Centonze,et al.  Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression , 2018, Front. Mol. Neurosci..

[28]  R. G. Correa,et al.  Dopamine: Functions, Signaling, and Association with Neurological Diseases , 2018, Cellular and Molecular Neurobiology.

[29]  S. Patten,et al.  Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. , 2018, Multiple sclerosis and related disorders.

[30]  A. Wróbel,et al.  Cannabinoids in depressive disorders , 2018, Life sciences.

[31]  J. Mann,et al.  Depression , 2018, The Lancet.

[32]  Y. Fang,et al.  Effects of tumor necrosis factor-α polymorphism on the brain structural changes of the patients with major depressive disorder , 2018, Translational Psychiatry.

[33]  A. Steptoe,et al.  Depressive symptoms predict incident chronic disease burden 10 years later: Findings from the English Longitudinal Study of Ageing (ELSA). , 2018, Journal of psychosomatic research.

[34]  S. Muthukumaraswamy,et al.  Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: A systematic review and meta-analysis. , 2018, Journal of psychiatric research.

[35]  M. Carta,et al.  Pharmacological management of depression in patients with multiple sclerosis , 2018, Expert Opinion on Pharmacotherapy.

[36]  M. Tremblay,et al.  Reduced Microglial Activity and Enhanced Glutamate Transmission in the Basolateral Amygdala in Early CNS Autoimmunity , 2018, The Journal of Neuroscience.

[37]  P. Calabresi,et al.  Multiple sclerosis and cognition: synaptic failure and network dysfunction , 2018, Nature Reviews Neuroscience.

[38]  P. Slominsky,et al.  Genetics Factors in Major Depression Disease , 2018, Front. Psychiatry.

[39]  E. Castrén,et al.  Effects of the Antidepressant Fluoxetine on the Somatostatin Interneurons in the Basolateral Amygdala , 2018, Neuroscience.

[40]  K. Seki,et al.  Molecular mechanism of noradrenaline during the stress-induced major depressive disorder , 2018, Neural regeneration research.

[41]  H. Steinbusch,et al.  Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression , 2018, Psychopharmacology.

[42]  Adwitia Dey,et al.  Insights into Macrophage Heterogeneity and Cytokine-Induced Neuroinflammation in Major Depressive Disorder , 2018, Pharmaceuticals.

[43]  C. Baecher-Allan,et al.  Effector T Cells in Multiple Sclerosis. , 2018, Cold Spring Harbor perspectives in medicine.

[44]  F. Piehl,et al.  Depression and fatigue in multiple sclerosis: Relation to exposure to violence and cerebrospinal fluid immunomarkers , 2018, Psychoneuroendocrinology.

[45]  R. Edden,et al.  Reduced GABA levels correlate with cognitive impairment in patients with relapsing-remitting multiple sclerosis , 2018, European Radiology.

[46]  G. Gamberini,et al.  Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment , 2018, CNS Drugs.

[47]  R. Lu,et al.  Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder , 2018, Psychoneuroendocrinology.

[48]  C. Pariante,et al.  Repeated lipopolysaccharide exposure modifies immune and sickness behaviour response in an animal model of chronic inflammation , 2018, Journal of psychopharmacology.

[49]  D. Centonze,et al.  Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake , 2018, Journal of Neuroinflammation.

[50]  A. Pastore,et al.  Vortioxetine exerts anti‐inflammatory and immunomodulatory effects on human monocytes/macrophages , 2018, British journal of pharmacology.

[51]  L. Steinman,et al.  Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine , 2017, Journal of Neuroimmunology.

[52]  D. Centonze,et al.  Interferon-γ causes mood abnormalities by altering cannabinoid CB1 receptor function in the mouse striatum , 2017, Neurobiology of Disease.

[53]  D. Centonze,et al.  Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study) , 2017, Journal of Neurology.

[54]  Li-Tao Yi,et al.  microRNA-124 targets glucocorticoid receptor and is involved in depression-like behaviors , 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[55]  D. Centonze,et al.  Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis , 2017, Neurology.

[56]  S. Nakagawa,et al.  Neural basis of major depressive disorder: Beyond monoamine hypothesis , 2017, Psychiatry and clinical neurosciences.

[57]  C. O. Brandão,et al.  Suicidal ideation, anxiety, and depression in patients with multiple sclerosis , 2017, Arquivos de Neuro-Psiquiatria.

[58]  S. Patten,et al.  Depression in multiple sclerosis , 2017, International review of psychiatry.

[59]  Lisa Koski,et al.  GABA and glutamate levels correlate with MTR and clinical disability: Insights from multiple sclerosis , 2017, NeuroImage.

[60]  Yong-Ku Kim,et al.  The influence of stress on neuroinflammation and alterations in brain structure and function in major depressive disorder , 2017, Behavioural Brain Research.

[61]  A. Bramanti,et al.  Cortical Plasticity in Depression , 2017, ASN neuro.

[62]  M. Keshavan,et al.  The neurobiology of depression: An integrated view. , 2017, Asian journal of psychiatry.

[63]  Simon Hametner,et al.  Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis , 2017, Brain : a journal of neurology.

[64]  C. Wolfson,et al.  Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis. , 2017, International journal of MS care.

[65]  B. Puri,et al.  A Comparison of Neuroimaging Abnormalities in Multiple Sclerosis, Major Depression and Chronic Fatigue Syndrome (Myalgic Encephalomyelitis): is There a Common Cause? , 2017, Molecular Neurobiology.

[66]  Allison C. Nugent,et al.  Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine , 2017, Biological Psychiatry.

[67]  W. Wick,et al.  Suppression of Th1 differentiation by tryptophan supplementation in vivo , 2017, Amino Acids.

[68]  J. Sheridan,et al.  Microglial recruitment of IL-1β producing monocytes to brain endothelium causes stress-induced anxiety , 2017, Molecular Psychiatry.

[69]  S. Mathew,et al.  Targeting glutamate signalling in depression: progress and prospects , 2017, Nature Reviews Drug Discovery.

[70]  A. Carvalho,et al.  Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders , 2017, Neuropsychopharmacology.

[71]  M. Filippi,et al.  Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis , 2017, Multiple sclerosis.

[72]  Bruce V. Taylor,et al.  Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression , 2017, Scientific Reports.

[73]  R. Marrie,et al.  Antidepressant Drug Treatment in Association with Multiple Sclerosis Disease-Modifying Therapy: Using Explorys in the MS Population. , 2016, International journal of MS care.

[74]  H. Lassmann,et al.  Multiple sclerosis: experimental models and reality , 2016, Acta Neuropathologica.

[75]  M. Maes,et al.  Immune-Inflammatory and Oxidative and Nitrosative Stress Biomarkers of Depression Symptoms in Subjects with Multiple Sclerosis: Increased Peripheral Inflammation but Less Acute Neuroinflammation , 2016, Molecular Neurobiology.

[76]  D. Mohr,et al.  Major depressive disorder , 2016, Nature Reviews Disease Primers.

[77]  D. Centonze,et al.  Interaction between interleukin-1β and type-1 cannabinoid receptor is involved in anxiety-like behavior in experimental autoimmune encephalomyelitis , 2016, Journal of Neuroinflammation.

[78]  S. Lipton,et al.  Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities , 2016, The Lancet Neurology.

[79]  D. Feuerbach,et al.  Antidepressant therapies inhibit inflammation and microglial M1-polarization. , 2016, Pharmacology & therapeutics.

[80]  C. Limatola,et al.  Fractalkine receptor deficiency impairs microglial and neuronal responsiveness to chronic stress , 2016, Brain, Behavior, and Immunity.

[81]  M. Fakhoury Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders , 2016, Molecular Neurobiology.

[82]  Deborah M. Miller,et al.  Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial , 2016, Journal of the Neurological Sciences.

[83]  S. Lévesque,et al.  Myeloid cell transmigration across the CNS vasculature triggers IL-1β–driven neuroinflammation during autoimmune encephalomyelitis in mice , 2016, The Journal of experimental medicine.

[84]  R. Dantzer Role of the Kynurenine Metabolism Pathway in Inflammation-Induced Depression: Preclinical Approaches. , 2016, Current topics in behavioral neurosciences.

[85]  P. Santos The role of inflammation in depression , 2016 .

[86]  P. Ragonese,et al.  A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study , 2016, Journal of the Neurological Sciences.

[87]  S. Wood,et al.  Neuroinflammation at the interface of depression and cardiovascular disease: Evidence from rodent models of social stress , 2016, Neurobiology of Stress.

[88]  S. Russo,et al.  Pathogenesis of depression: Insights from human and rodent studies , 2016, Neuroscience.

[89]  Z. Baloch,et al.  Pathogenetic and Therapeutic Applications of Tumor Necrosis Factor-α (TNF-α) in Major Depressive Disorder: A Systematic Review , 2016, International journal of molecular sciences.

[90]  R. Shelton,et al.  A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. , 2016, The American journal of psychiatry.

[91]  R. Duman,et al.  Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. , 2016, Drug discovery today.

[92]  Xia Zhang,et al.  Role of neuroinflammation in neurodegenerative diseases (Review) , 2016, Molecular medicine reports.

[93]  T. Olsson,et al.  Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms , 2016, Brain, Behavior, and Immunity.

[94]  M. J. Bellizzi,et al.  Platelet-Activating Factor Receptors Mediate Excitatory Postsynaptic Hippocampal Injury in Experimental Autoimmune Encephalomyelitis , 2016, The Journal of Neuroscience.

[95]  D. Centonze,et al.  Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis , 2015, Nature Reviews Neurology.

[96]  L. Luo,et al.  Organization of the Locus Coeruleus-Norepinephrine System , 2015, Current Biology.

[97]  Klaus P. Ebmeier,et al.  Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder , 2015, Brain, Behavior, and Immunity.

[98]  M. Furtado,et al.  Examining the role of neuroinflammation in major depression , 2015, Psychiatry Research.

[99]  D. Centonze,et al.  The interplay between inflammatory cytokines and the endocannabinoid system in the regulation of synaptic transmission , 2015, Neuropharmacology.

[100]  Manuel A. Friese,et al.  Immunopathology of multiple sclerosis , 2015, Nature Reviews Immunology.

[101]  N. Toschi,et al.  Structural ‘connectomic’ alterations in the limbic system of multiple sclerosis patients with major depression , 2015, Multiple sclerosis.

[102]  D. Centonze,et al.  Exploring the role of microglia in mood disorders associated with experimental multiple sclerosis , 2015, Front. Cell. Neurosci..

[103]  G. Aghajanian,et al.  Optogenetic stimulation of infralimbic PFC reproduces ketamine’s rapid and sustained antidepressant actions , 2015, Proceedings of the National Academy of Sciences.

[104]  P. Fox,et al.  Identification of a common neurobiological substrate for mental illness. , 2015, JAMA psychiatry.

[105]  V. De Rosa,et al.  Animal models of Multiple Sclerosis , 2015, European Journal of Pharmacology.

[106]  Q. Pittman,et al.  Microglia-Dependent Alteration of Glutamatergic Synaptic Transmission and Plasticity in the Hippocampus during Peripheral Inflammation , 2015, The Journal of Neuroscience.

[107]  Paul B Fitzgerald,et al.  THETA‐BURST STIMULATION: A NEW FORM OF TMS TREATMENT FOR DEPRESSION? , 2015, Depression and anxiety.

[108]  Alan A. Wilson,et al.  Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. , 2015, JAMA psychiatry.

[109]  D. Centonze,et al.  Dopaminergic dysfunction is associated with IL-1β-dependent mood alterations in experimental autoimmune encephalomyelitis , 2015, Neurobiology of Disease.

[110]  Jingyuan Chen,et al.  Microglia activation regulates GluR1 phosphorylation in chronic unpredictable stress-induced cognitive dysfunction , 2015, Stress.

[111]  D. Centonze,et al.  Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53 , 2014, Molecular Neurodegeneration.

[112]  Peter B. Jones,et al.  Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. , 2014, JAMA psychiatry.

[113]  A. Feinstein,et al.  The link between multiple sclerosis and depression , 2014, Nature Reviews Neurology.

[114]  G. Rosoklija,et al.  Microglia of Prefrontal White Matter in Suicide , 2014, Journal of neuropathology and experimental neurology.

[115]  Etienne Sibille,et al.  Why Are Cortical GABA Neurons Relevant to Internal Focus in Depression? A cross-level model linking cellular, biochemical, and neural network findings , 2014, Molecular Psychiatry.

[116]  D. Centonze,et al.  Interleukin-1β Promotes Long-Term Potentiation in Patients with Multiple Sclerosis , 2014, NeuroMolecular Medicine.

[117]  B. Giros,et al.  Morphometric characterization of microglial phenotypes in human cerebral cortex , 2014, Journal of Neuroinflammation.

[118]  G. Mead,et al.  Potential disease-modifying effects of selective serotonin reuptake inhibitors in multiple sclerosis: systematic review and meta-analysis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[119]  J. Nacher,et al.  Chronic stress alters inhibitory networks in the medial prefrontal cortex of adult mice , 2013, Brain Structure and Function.

[120]  S. Kirzinger,et al.  Relationship between disease-modifying therapy and depression in multiple sclerosis. , 2013, International journal of MS care.

[121]  Q. Pittman,et al.  Altered cognitive-emotional behavior in early experimental autoimmune encephalitis – Cytokine and hormonal correlates , 2013, Brain, Behavior, and Immunity.

[122]  G. Baker,et al.  Fluoxetine and citalopram decrease microglial release of glutamate and d-serine to promote cortical neuronal viability following ischemic insult , 2013, Molecular and Cellular Neuroscience.

[123]  D. Centonze,et al.  Interleukin-1β Alters Glutamate Transmission at Purkinje Cell Synapses in a Mouse Model of Multiple Sclerosis , 2013, The Journal of Neuroscience.

[124]  R. Torta,et al.  Pharmacological Management of Depression in Patients with Cancer: Practical Considerations , 2013, Drugs.

[125]  M. Banasr,et al.  From Pathophysiology to Novel Antidepressant Drugs: Glial Contributions to the Pathology and Treatment of Mood Disorders , 2013, Biological Psychiatry.

[126]  C. Benkelfat,et al.  The neurobiology of depression—revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies† , 2013, Philosophical Transactions of the Royal Society B: Biological Sciences.

[127]  P. Calabresi,et al.  Effects of central and peripheral inflammation on hippocampal synaptic plasticity , 2013, Neurobiology of Disease.

[128]  D. Centonze,et al.  Inflammation Subverts Hippocampal Synaptic Plasticity in Experimental Multiple Sclerosis , 2013, PloS one.

[129]  R. McLaughlin,et al.  Upregulation of CB1 receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure , 2013, Behavioural Brain Research.

[130]  F. Kirchhoff,et al.  Microglia: New Roles for the Synaptic Stripper , 2013, Neuron.

[131]  D. Centonze,et al.  TNF-α-mediated anxiety in a mouse model of multiple sclerosis , 2012, Experimental Neurology.

[132]  T. Pickersgill,et al.  Multiple sclerosis relapses and depression. , 2012, Journal of psychosomatic research.

[133]  I. Craig,et al.  Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline ‘Predictors' and Longitudinal ‘Targets' , 2012, Neuropsychopharmacology.

[134]  Laurent Descarries,et al.  The neurobiology of depression—revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.

[135]  R. Claycomb,et al.  Interleukin-1β in Central Nervous System Injury and Repair. , 2012, European journal of neurodegenerative disease.

[136]  R. Ransohoff,et al.  Animal models of multiple sclerosis: the good, the bad and the bottom line , 2012, Nature Neuroscience.

[137]  P. Piccini,et al.  Imaging of Microglia in Patients with Neurodegenerative Disorders , 2012, Front. Pharmacol..

[138]  D. Centonze,et al.  GABAergic signaling and connectivity on Purkinje cells are impaired in experimental autoimmune encephalomyelitis , 2012, Neurobiology of Disease.

[139]  H. Son,et al.  Neuropathological abnormalities of astrocytes, GABAergic neurons, and pyramidal neurons in the dorsolateral prefrontal cortices of patients with major depressive disorder , 2012, European Neuropsychopharmacology.

[140]  J. Nacher,et al.  Expression of PSA-NCAM and synaptic proteins in the amygdala of psychiatric disorder patients. , 2012, Journal of psychiatric research.

[141]  G. Sanacora,et al.  Towards a glutamate hypothesis of depression An emerging frontier of neuropsychopharmacology for mood disorders , 2012, Neuropharmacology.

[142]  D. Centonze,et al.  Interleukin‐1β causes synaptic hyperexcitability in multiple sclerosis , 2012, Annals of neurology.

[143]  E. Castrén,et al.  Fear Erasure in Mice Requires Synergy Between Antidepressant Drugs and Extinction Training , 2011, Science.

[144]  A. Teixeira,et al.  Behavioral investigation of mice with experimental autoimmune encephalomyelitis. , 2011, Arquivos de neuro-psiquiatria.

[145]  Zhen Yan,et al.  The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission , 2011, Nature Reviews Neuroscience.

[146]  Gustavo Tenorio,et al.  The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE) , 2011, Brain, Behavior, and Immunity.

[147]  Anthony Feinstein,et al.  Multiple sclerosis and depression , 2011, Multiple sclerosis.

[148]  P. Moore,et al.  Endocannabinoid system dysfunction in mood and related disorders , 2011, Acta psychiatrica Scandinavica.

[149]  Serge Marchand,et al.  A Deficit in Peripheral Serotonin Levels in Major Depressive Disorder but Not in Chronic Widespread Pain , 2011, The Clinical journal of pain.

[150]  G. Juckel,et al.  Inflammation modulates anxiety in an animal model of multiple sclerosis , 2011, Behavioural Brain Research.

[151]  C. Ionete,et al.  Relationships between multiple sclerosis and depression. , 2011, The Journal of neuropsychiatry and clinical neurosciences.

[152]  Massimiliano Calabrese,et al.  Cortical pathology and cognitive impairment in multiple sclerosis , 2011, Expert review of neurotherapeutics.

[153]  S. Janelidze,et al.  Cytokine levels in the blood may distinguish suicide attempters from depressed patients , 2011, Brain, Behavior, and Immunity.

[154]  Zheng Zachory Wei,et al.  Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. , 2011, Current Alzheimer research.

[155]  M. Zappia,et al.  Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study , 2010, Multiple sclerosis.

[156]  R. Dantzer,et al.  CSF Concentrations of Brain Tryptophan and Kynurenines during Immune Stimulation with IFN-alpha: Relationship to CNS Immune Responses and Depression , 2009, Molecular Psychiatry.

[157]  Alessandro Martorana,et al.  Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis , 2009, Neurobiology of Disease.

[158]  Andrew H. Miller,et al.  Cytokines and Glucocorticoid Receptor Signaling , 2009, Annals of the New York Academy of Sciences.

[159]  Jing Du,et al.  A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. , 2009, The international journal of neuropsychopharmacology.

[160]  Charles L. Raison,et al.  Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression , 2009, Biological Psychiatry.

[161]  D. Centonze,et al.  Inflammation Triggers Synaptic Alteration and Degeneration in Experimental Autoimmune Encephalomyelitis , 2009, The Journal of Neuroscience.

[162]  D. Centonze,et al.  Adaptations of Striatal Endocannabinoid System During Stress , 2009, Molecular Neurobiology.

[163]  Sung‐Hwa Yoon,et al.  Fluoxetine affords robust neuroprotection in the postischemic brain via its anti‐inflammatory effect , 2009, Journal of neuroscience research.

[164]  Jaclyn I. Wamsteeker,et al.  Altered chloride homeostasis removes synaptic inhibitory constraint of the stress axis , 2009, Nature Neuroscience.

[165]  G. Juckel,et al.  Review: Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment , 2009, Therapeutic advances in neurological disorders.

[166]  H. Critchley,et al.  Peripheral Inflammation is Associated with Altered Substantia Nigra Activity and Psychomotor Slowing in Humans , 2008, Biological Psychiatry.

[167]  S. Gwaltney-Brant,et al.  Serotonin: a review. , 2008, Journal of veterinary pharmacology and therapeutics.

[168]  M. van Buchem,et al.  Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[169]  E. Maron,et al.  Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[170]  R. Belmaker,et al.  Major depressive disorder. , 2008, The New England journal of medicine.

[171]  M. Banasr,et al.  Regulation of neurogenesis and gliogenesis by stress and antidepressant treatment. , 2007, CNS & neurological disorders drug targets.

[172]  P. O’Connell,et al.  Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. , 2007, Blood.

[173]  P. Scully,et al.  Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. , 2007, Journal of psychiatric research.

[174]  R. Dantzer,et al.  Named Series: Twenty Years of Brain, Behavior, and Immunity Twenty years of research on cytokine-induced sickness behavior , 2007 .

[175]  Gregor Hasler,et al.  Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. , 2007, Archives of general psychiatry.

[176]  Andrew H. Miller,et al.  Cytokine-effects on glucocorticoid receptor function: Relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression , 2007, Brain, Behavior, and Immunity.

[177]  A. Schene,et al.  Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies , 2007, Molecular Psychiatry.

[178]  S. Gold,et al.  Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. , 2006, Neurologic clinics.

[179]  D. Fuchs,et al.  Monitoring tryptophan metabolism in chronic immune activation. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[180]  M. McCabe Mood and self-esteem of persons with multiple sclerosis following an exacerbation. , 2005, Journal of psychosomatic research.

[181]  B. Bogerts,et al.  Volume deficits of subcortical nuclei in mood disorders , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[182]  S. Khoury,et al.  Cytokines in multiple sclerosis: from bench to bedside. , 2005, Pharmacology & therapeutics.

[183]  George P Chrousos,et al.  Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. , 2005, The Journal of clinical endocrinology and metabolism.

[184]  J. Francis,et al.  Neuroendocrine and cytokine profile of chronic mild stress-induced anhedonia , 2005, Physiology & Behavior.

[185]  W. Drevets,et al.  Discovering Endophenotypes for Major Depression , 2004, Neuropsychopharmacology.

[186]  M. Bear,et al.  LTP and LTD An Embarrassment of Riches , 2004, Neuron.

[187]  R. Spengler,et al.  Brain-Derived Tumor Necrosis Factor-α and Its Involvement in Noradrenergic Neuron Functioning Involved in the Mechanism of Action of an Antidepressant , 2004, Journal of Pharmacology and Experimental Therapeutics.

[188]  C. Pozzilli,et al.  Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis , 2003, Multiple sclerosis.

[189]  Y. Pollak,et al.  The EAE-associated behavioral syndrome I. Temporal correlation with inflammatory mediators , 2003, Journal of Neuroimmunology.

[190]  I. Goshen,et al.  Experimental autoimmune encephalomyelitis-associated behavioral syndrome as a model of ‘depression due to multiple sclerosis’ , 2002, Brain, Behavior, and Immunity.

[191]  E. Zorrilla,et al.  The Relationship of Depression and Stressors to Immunological Assays: A Meta-Analytic Review , 2001, Brain, Behavior, and Immunity.

[192]  T. J. Nickola,et al.  Antidepressant Drug-Induced Alterations in Neuron-Localized Tumor Necrosis Factor-α mRNA and α2-Adrenergic Receptor Sensitivity , 2001 .

[193]  J. Kelly,et al.  Olfactory Bulbectomy Provokes a Suppression of Interleukin-1β and Tumour Necrosis Factor-α Production in Response to an in vivo Challenge with Lipopolysaccharide: Effect of Chronic Desipramine Treatment , 1999, Neuroimmunomodulation.

[194]  B. Roth,et al.  Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression∗ ∗ See accompanying Editorial, in this issue. , 1999, Biological Psychiatry.

[195]  E. Bosmans,et al.  Negative Immunoregulatory Effects of Antidepressants: Inhibition of Interferon-γ and Stimulation of Interleukin-10 Secretion , 1999, Neuropsychopharmacology.

[196]  Michael Maes,et al.  Evidence for an immune response in major depression: A review and hypothesis , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[197]  R. S. Smith The macrophage theory of depression. , 1991, Medical hypotheses.

[198]  D. Ditor,et al.  The effects of acute aerobic exercise on mood and inflammation in individuals with multiple sclerosis and incomplete spinal cord injury. , 2019, NeuroRehabilitation.

[199]  Yan Wang,et al.  Behavioral defects induced by chronic social defeat stress are protected by Momordica charantia polysaccharides via attenuation of JNK3/PI3K/AKT neuroinflammatory pathway. , 2019, Annals of translational medicine.

[200]  D. Reich,et al.  Multiple Sclerosis , 2018, The New England journal of medicine.

[201]  J. Meyer,et al.  Neuroprogression and Immune Activation in Major Depressive Disorder. , 2017, Modern trends in pharmacopsychiatry.

[202]  Andrew H. Miller,et al.  Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders , 2017, Neuropsychopharmacology.

[203]  Zhengxue Qiao,et al.  CREB1 gene polymorphisms combined with environmental risk factors increase susceptibility to major depressive disorder (MDD). , 2015, International journal of clinical and experimental pathology.

[204]  D. Steffens,et al.  Basolateral amygdala volume and cell numbers in major depressive disorder: a postmortem stereological study , 2014, Brain Structure and Function.

[205]  T. Hansen,et al.  Promoter variants in IL18 are associated with onset of depression in patients previously exposed to stressful-life events. , 2012, Journal of affective disorders.

[206]  Andrew H. Miller,et al.  Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior , 2012, Neuropsychopharmacology.

[207]  G. Martino,et al.  Animal models of multiple sclerosis. , 2009, Methods in molecular biology.

[208]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[209]  Andrew H. Miller,et al.  Cytokines sing the blues: inflammation and the pathogenesis of depression. , 2006, Trends in immunology.

[210]  T. J. Nickola,et al.  Antidepressant drug-induced alterations in neuron-localized tumor necrosis factor-alpha mRNA and alpha(2)-adrenergic receptor sensitivity. , 2001, The Journal of pharmacology and experimental therapeutics.